Purchase Order HT001416P1413
Award Date 10/3/16
Potential Completion Date 10/2/17
Potential Value $128K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Health Agency has awarded Cerus Corporation, a for-profit manufacturer of biomedical products, a $87,166.08 firm fixed price purchase order contract to provide the INTERCEPT Blood System for Platelets. This pathogen reduction technology uses riboflavin and UV light to inactivate viruses, bacteria, protozoa, and contaminating white blood cells in platelet components. The contract, which does not have a set-aside designation, will run through June 18, 2024. Cerus has received over 20...
- The Defense Health Agency awarded Cerus Corporation, a biomedical products company, a firm-fixed-price purchase order contract worth $190,080.00 for the supply of INTERCEPT Platelet Processing Sets and INTERCEPT Platelet Processing Sets with Dual Storage Containers. The contract is a sole-source award due to the proprietary nature of Cerus Corporation's INTERCEPT Blood System technology, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components. This pathogen...
- This firm-fixed-price purchase order was awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company, for the provision of INTERCEPT Platelet Processing Sets. Valued at $137,664.00, the contract does not have a set-aside designation. Cerus has received over 20 previous prime federal contract awards from agencies including the DoD, VA, and HHS to provide pathogen reduction technologies, equipment, and associated services to support military and veterans' medical...
- This federal contract award was issued by the Bureau of Medicine and Surgery, a defense agency, to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The $138,800 firm-fixed-price contract is for the supply of INTERCEPT Illuminator 60 Hz equipment and INTERCEPT Platelet Processing Sets with Dual Storage, as well as related services, to support the agency's blood product safety requirements. Cerus Corporation's proprietary INTERCEPT Blood System uses...
- This is a firm fixed-price purchase order awarded by the Defense Health Agency (DHA) to Cerus Corporation, a for-profit manufacturer of the INTERCEPT Blood System, a pathogen reduction technology for platelets and plasma. The $369,384 contract is for the supply of INTERCEPT Platelet Processing Sets, Dual Storage Containers, and maintenance services for INTERCEPT Blood System illuminators to support medical readiness and blood product safety at military healthcare facilities. The contract has...
- This is a firm fixed-price purchase order contract awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The contract is for the delivery of INTERCEPT Platelet Processing Sets, which are used to inactivate pathogens in blood platelets. The contract has a ceiling value of $295,760.00 and an ultimate completion date of January 31, 2022. Cerus Corporation has consistently secured sole-source...
- The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
- The Defense Health Agency awarded a $104,256 firm fixed-price purchase order to Cerus Corporation on September 30, 2019, for INTERCEPT Platelet Small Volume Sets, with performance through September 3, 2024. The contract was awarded without a set-aside designation to Cerus Corporation, a Concord, California-based biomedical products manufacturer specializing in blood safety technologies. Cerus's INTERCEPT Blood System uses riboflavin and ultraviolet light technology to inactivate pathogens in...
- This is a firm fixed price purchase order contract awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that manufactures the INTERCEPT Blood System technology for pathogen reduction in blood components. The contract is for the DROP SHIPMENT OF INTERCEPT DUAL, with a potential value of $66,624.00 and a completion date of January 1, 2024. Cerus Corporation, the prime contractor, is a for-profit manufacturer that has received over 20 federal contract awards from...
- The Defense Health Agency awarded a $199,584 firm fixed-price purchase order to Cerus Corporation on January 5, 2024, for the procurement of Intercept Platelet Sets (PN INT2140B). The contract, which carries an ultimate completion date of September 30, 2028, will be performed at Cerus Corporation's facility in Concord, California. This award represents a continuation of the Defense Health Agency's established relationship with Cerus Corporation for blood safety technologies, specifically the...